Recombinant insulinlike growth factor-I as therapy in states of altered carbohydrate homeostasis

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 1, 1997, Pages 16-25

  Moses, Alan C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001860657     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199702000-00003     Document Type: Article

References (66)

1. Salmon WD, Daughaday WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957, 49:825-836.
2. Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978, 253:2769-2776.
3. Rinderknecht E, Humbel R: Primary structure of human insulin-like growth factor II. FEBS Lett 1978, 89:283-286.
4. Blundell TL, Bedarkar S, Humbel RE: Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors. Fed Proc 1983, 42:2592-2597.
5. Rotwein P: Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors 1991, 5:3-18.
6. Chan SJ, Nagamatsu S, Cao QP, Steiner DF: Structure and evolution of insulin and insulin-like growth factors in chordates. Prog Brain Res 1992, 92:15-24.
7. King GL, Kahn CR, Samuels B, Danho W, Bullesbach EE, Gattner HG: Synthesis and characterization of molecular hybrids of insulin and insulin-like growth factor I: the role of the A-chain extension peptide. J Biol Chem 1982, 257:10869-10873.
8. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34. Excellent recent review paper on the IGFs and their binding proteins. A good starting place for the newcomer to this field.
9. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, LeBon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y: Insulin-like growth factor I receptor I primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986, 5:2503-2512.
10. LeRoith D: Insulin-like growth factor receptors and binding proteins. Baillieres Clin Endocrinol Metab 1996, 10:49-73. Points out the similarities and some of the differences between the insulin and IGF-I receptors and how these may distinguish the biologic activities of the two receptors.
11. Araki E, Lipes MA, Patti ME, Bruning JC, Haag B 3rd, Johnson RS, Kahn CR: Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 1994, 372:186-190.
12. Sasaoka T, Ishiki M, Sawa T, Ishihara H, Takata Y, Imamura T, Usui I, Olefsky JM, Kobayashi M: Comparison of the insulin and insulin-like growth factor 1 mitogenic intracellular signalling pathways. Endocrinology 1996, 137:4427-4434. Interesting paper that details the common utilization by the insulin and IGF-I receptors of specific signal transduction molecules involved in the mitogenic response to these factors.
13. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK: Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988, 81:976-981.
14. Zapf J: Physiological role of the insulin-like growth factor binding proteins. Eur J Endocrinol 1995, 132:645-654.
15. Mohan S, Baylink DJ: Insulin-like growth factor (IGF)-binding proteins in serum: do they have additional roles besides modulating the endocrine IGF actions? J Clin Endocrinol Metab 1996, 81:3817-3820. A recent succinct discussion of the IGFBPs, their regulation, and their potential physiologic role. Provides some perspective on the subject.
16. Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD: Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 1991, 266:18868-18876.
17. Bar RS, Boes M, Dake BL, Sandra A, Bayne M, Cascieri M, Booth BA: Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I. Endocrinology 1990, 127:3243-3245.
18. Clemmons DR: Role of post translational modifications in modifying the biologic activity of insulin like growth factor binding proteins. Adv Exp Med Biol 1993, 343:245-253.
19. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in Type II diabetes. Diabetes 1996, 45:91-100. Open-label study evaluating rhIGF-I as monotherapy for 6 weeks in type II diabetes and assessing insulin sensitivity before and after rhIGF-I using the Bergman model (frequently sampled intravenous glucose tolerance testing).
20. Rechler MM, Zapf J, Nissley SP, Froesch ER, Moses AC, Podskalny JM, Schilling EE, Humbel RE: Interactions of insulin-like growth factors I and II and multiplication stimulating activity with receptors and serum carrier proteins. Endocrinology 1980, 107:1451-1459.
21. Guler H-P, Zapf J, Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987, 317:137-140.
22. Elahi D, McAloon-Dyke M, Fukagawa NK, Sclater AL, Wong GA, Shannon RP, Minaker KL, Miles JM, Rubenstein AH, Vanderpol CJ, Guler H-P, Good WR, Seamna JJ, Wolfe RR: Effects of recombinant human IGF-I on glucose and leucine kinetics in men. Am J Physiol 1993, 265:E831-E838.
23. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS: Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 1992, 262:E130-E133.
24. Hartman ML, Clayton PE, Johnson M, Celniker A, Perlman AJ, Alberti KG, Thorner MO: A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. J Clin Invest 1993, 91:2453-2462.
25. Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ: Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest 1995, 96:1722-1729.
26. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS: Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin: dose-response relationships in healthy young and middle-aged adults. J Clin Invest 1994, 93:1131-1139.
27. Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, Sherwin RS: Insulin-infusion-pump treatment of diabetes: influence of improved metabolic control on plasma somatomedin levels. N Engl J Med 1981, 305:303-307.
28. Clayton KL, Holly JM, Carlsson LM, Jones J, Cheetham TD, Taylor AM, Dunger DB: Loss of the normal relationships between growth hormone, growth hormone binding protein and insulin-like growth factor I in adolescents with insulin-dependent diabetes mellitus. Clin Endocrinol 1994, 41:517-524.
29. Cotterill AM, Daly F, Holly JMP, Hughes SC, Camacho-Hubner C, Abdulla AF, Gale EAM, Savage MO: The "dawn phenomenon" in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. Clin Endocrinol 1995, 43:567-574.
30. Bereket A, Lang CH, Blethen SL, Gelato MC, Fan J, Frost RA, Wilson TA: Effect of insulin on the insulin-like growth factor system in children with new-onset insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995, 80:1312-1317. Clearly demonstrates in a small prospective study that serum IGF-I levels are dependent on insulin therapy in type I diabetes mellitus early in the course of treatment.
31. Bereket A, Wilson TA, Blethen SL, Sakurai Y, Herndon DN, Wolfe RR, Lang CH: Regulation of the acid-labile subunit of the insulin-like growth factor terniary complex in patients with insulin-dependent diabetes mellitus and severe burns. Clin Endocrinol 1996, 44:525-532.
32. Bereket A, Lang CH, Blethen SL, Wilson TA: Insulin-like growth factor-binding protein-2 and insulin: studies in children with type 1 diabetes mellitus and maturity-onset diabetes of the young. J Clin Endocrinol Metab 1995, 80:3647-3652.
33. Shisko PI, Dreval AV, Abugova IA, Zajarny IU, Goncharov VC: Insulin-like growth factors and binding proteins in patients with recent-onset type I (insulin-independent) diabetes mellitus: Influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 1995, 25:1-12. Somewhat unconventional approach to insulin administration (via umbilical vein) clearly demonstrating the importance of hepatic insulin delivery to IGF-I and IGFBP-1 levels in patients with type I diabetes mellitus.
34. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld R, Tauber JP: Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabete Metab 1996, 22:245-250. Study that essentially confirms the findings of Shisko et al. (Diabetes Res Clin Pract 1995, 25:1-12) using conventional intraperitoneal insulin administration.
35. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld R, Tauber JP: Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabete Metab 1996, 22:245-250. Study that essentially confirms the findings of Shisko et al. (Diabetes Res Clin Pract 1995, 25:1-12) using conventional intraperitoneal insulin administration.
36. Tan K, Baxter RC: Serum insulin-like growth factor I levels in adult diabetic patients: the effect of age. J Clin Endocrinol Metab 1986, 63:651-655.
37. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER: Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991, 34:675-679.
38. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC: Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N Engl J Med 1990, 323:1425-1426.
39. Usala AL, Madigan T, Burguera B, Cefalu W, Sinha MK, Powell JG, Usala SJ: High dose intravenous, but not low dose subcutaneous, insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus. J Clin Endocrinol Metab 1994, 79:435-440.
40. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC: Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the Type A syndrome of insulin resistance. J Clin Endocrinol Metab 1994, 79:205-210.
41. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS: Insulin-like growth factor (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995, 28(suppl):185-194. Provides detailed studies of rhIGF-I's action in severe insulin resistance in six subjects with diverse phenotypes of insulin resistance.
42. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M, et al.: Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance. Diabetes 1993, 42:696-705.
43. Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE, Riesen WF, Schoenle EJ, Froesch ER: Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994, 131:251-257.
44. Nakashima N, Umeda F, Yanase T, Nawata H: Insulin resistance associated with substitution of histidine for arginine 252 in the alpha-subunit of the human insulin receptor: trial of insulin-like growth factor I injection therapy to enhance insulin sensitivity. J Clin Endocrinol Metab 1995, 80:3662-3667. Single case study that demonstrates the ability of rhIGF-I to improve glycemic control in a patient with documented mutation in the a subunit of the insulin receptor. Provides "proof of principle" that IGF-I works through mechanisms independent of the insulin receptor.
45. Ishihama H, Suzuki Y, Muramatsu K, Nagai M, Kokubo M, Shiraya H, Kawakita A, Nishimura Y, Imamura T, Kobayashi M: Long-term follow up in type A insulin resistant syndrome treated by insulin-like growth factor I. Arch Dis Child 1994, 71:144-146.
46. Dozio N, Scavini M, Beretta A, Sartori S, Meschi F, Sarugeri E, Pozza G: In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor. J Clin Endocrinol Metab 1995, 80:1325-1328.
47. Moller DE, Cohen O, Yamaguchi Y, Assiz R, Grigorescu F, Eberle A, Morrow A, Moses AC, Flier JS: Prevalence of mutations in the insulin receptor gene in subjects with features of the Type A syndrome of insulin resistance. Diabetes 1994, 43:247-255.
48. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER: Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992, 90:2234-2241.
49. Schalch DS, Turman NJ, Marcsisin VS, Heffeman M, Guler HP: Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 1993, 77:1563-1568.
50. Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler H-P: Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994, 43:369-374.
51. Young SC, Clemmons DR: Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections in noninsulin-dependent diabetics. J Clin Endocrinol Metab 1994, 78:609-614.
52. RhIGF-I in NIDDM Study Group: Evidence from a dose-ranging study that recombinant insulin-like growth factor I (RhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus (NIDDM) [abstract]. Diabetes 1996, 45(suppl 2):27A.
53. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC: Insulin-like growth factor binding protein-1 modulates blood glucose levels. Endocrinology 1991, 129:2254-2256.
54. Bach MA, Chin E, Bondy CA: The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994, 79:1040-1045.
55. Cheetham TD, Clayton KL, Taylor AM, Holly J, Matthews DR, Dunger DB: The effects of recombinant human insulin-tike growth factor I on growth hormone secretion in adolescents with insulin dependent diabetes mellitus. Clin Endocrinol 1994, 40:515-522.
56. Cheetham TD, Taylor A, Holly JM, Clayton K, Cwyfan-Hughes S, Dunger DB: The effects of recombinant human insulin-like growth factor-I (IGF-I) administration on the levels of IGF-I, IGF-II and IGF-binding proteins in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1994, 142:367-374.
57. 1c.
58. 1c.
59. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A, Baserga R: Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994, 14:3604-3612.
60. Neuenscwander S, Roberts CT Jr, LeRoith D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor anti-sense ribonucleic acid. Endocrinology 1995, 136:4298-4303.
61. Yee D, Jackson JG, Kozelsky TW, Figueroa JA: Insulin-like growth factor binding protein I expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells. Cell Growth Differ 1994, 5:73-77.
62. Jialal I, Crettaz M, Hachiya HL, Kahn CR, Moses AC, Buzney SM, King GL: Characterization of the receptors for insulin and the insulin-like growth factors on micro- and macrovascular tissues. Endocrinology 1985, 117:1222-1229.
63. Hussain MA, Studer K, Messmer EP, Froesch E: Treatment with insulin-like growth factor I alters capillary permeability in skin and retina. Diabetes 1995, 44:1209-1212. Carefully performed study that quantitates the effects of rhIGF-I on vascular permeability in humans.
64. Grant M, Russell B, Fitzgerald C, Merimee TJ: Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes 1986, 35:416-466.
65. Lee HC, Lee KW, Chung CH, Chung YS, Lee EJ, Lim SK, Kim KR, Huh KB, Lee SC, Kwon OW: IGF-I in serum and vitreous fluid in patients with diabetic proliferate retinopathy. Diabetes Res Clin Pract 1994, 24:85-88.
66. Wang Q, Dill DG, Klein R, Klein BE, Moss SE: Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 1995, 44:161-164.